Annual report pursuant to Section 13 and 15(d)

Consolidated Statement of Changes in Stockholders' Deficit

v3.7.0.1
Consolidated Statement of Changes in Stockholders' Deficit - USD ($)
Common Stock [Member]
Additional Paid-In Capital [Member]
Deferred Compensation [Member]
Accumulated Deficit [Member]
Total
Balance at Dec. 31, 2014 $ 63,886 $ 46,908,249 $ (294,264) $ (49,892,282) $ (3,214,411)
Balance, shares at Dec. 31, 2014 63,885,930        
Effect of merger with Cardax Pharmaceuticals, Inc $ (1,402) 1,402
Effect of merger with Cardax Pharmaceuticals, Inc, shares (1,402,426)        
Restricted stock issuances $ 6,021 1,800,201 1,806,222
Restricted stock issuances, shares 6,020,725        
Common stock grants to independent directors $ 458 116,209 116,667
Common stock grants to independent directors, shares 458,170        
Common stock grants to investor relations $ 100 44,900 45,000
Common stock grants to investor relations, shares 100,000        
Deferred compensation 294,264 294,264
Stock based compensation - options 1,409,592 1,409,592
Stock based compensation - warrants 48,700 48,700
Stock option exercise $ 25 3,935 $ 3,960
Stock option exercise, shares 25,556       (41,851)
Net loss (4,257,875) $ (4,257,875)
Balance at Dec. 31, 2015 $ 69,088 50,333,188 (54,150,157) (3,747,881)
Balance, shares at Dec. 31, 2015 69,087,955        
Restricted stock issuances $ 14,013 1,106,987 1,121,000
Restricted stock issuances, shares 14,012,500        
Common stock grants to independent directors $ 468 41,198 41,666
Common stock grants to independent directors, shares 468,254        
Common stock grants to investor relations $ 1,500 105,000 106,500
Common stock grants to investor relations, shares 1,500,000        
Stock based compensation - options 376,896 376,896
Stock based compensation - warrants        
Stock option exercise        
Net loss (1,783,705) (1,783,705)
Balance at Dec. 31, 2016 $ 85,069 $ 51,963,269 $ (55,933,862) $ (3,885,524)
Balance, shares at Dec. 31, 2016 85,068,709